InflaRx N.V. is a clinical-stage biopharmaceutical company focused on developing inhibitors targeting the C5a complement pathway, an inflammatory mediator implicated in autoimmune and inflammatory diseases. The company is headquartered in Jena, Germany, with operations in the United States, and operates with a workforce of 74 full-time employees.
The company's lead asset is vilobelimab, a first-in-class intravenous anti-C5a monoclonal antibody that completed Phase III trials for hidradenitis suppurativa, a chronic inflammatory skin condition. The compound is also in Phase II development for anti-neutrophil cytoplasm antibody-associated vasculitis and is being explored in Phase IIa studies for pyoderma gangraenosum. Additionally, vilobelimab is in Phase II evaluation for PD-1/PD-L1 inhibitor-resistant cutaneous squamous cell carcinoma and was investigated for COVID-19-related acute respiratory distress syndrome. InflaRx maintains a pipeline that includes INF904, an oral small-molecule candidate in development for chronic inflammatory and autoimmune diseases, and IFX002 in preclinical stages.
The company has established research collaborations and supply agreements with major pharmaceutical partners, including Merck & Co. and Beijing Defengrei Biotechnology Co. Ltd. As a clinical-stage entity, InflaRx does not generate meaningful product revenues and remains dependent on capital funding to support ongoing clinical development programs.
No 10-K filings found.